AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 182 min read$MLTX

Bodenstedt Matthias sold $352K of MLTX

Bodenstedt Matthias (Chief Financial Officer) sold 17,876 shares of MoonLake Immunotherapeutics (MLTX) at an average of $19.67 ($19.60–$19.68, $0.35M total) across 2 trades over 2026-06-17 to 2026-06-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Bodenstedt Matthias
Published Jun 18, 2026, 10:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 18, 2026, 10:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MLTX
Neutral
medium confidence
Mentioned
$MLTX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MLTXNeutralLow
01

Why it matters

The newest fact is the CFO’s open-market sale details (shares, price range, total value) executed under a pre-arranged 10b5-1 plan.

02

Market read

Primarily a sentiment/positioning datapoint; likely insufficient to drive a fundamental repricing absent other catalysts.

03

What to watch

The sale size is moderate relative to typical liquidity; without additional context (e.g., multiple insiders selling, option exercises, or concurrent news), the signal is weak.

Relevance 3/10Novelty 3/10Timing: filed 2026-06-18 after-hours; reflects sales executed 6/17–6/18

Background

The article is an SEC Form 4 insider transaction disclosure for MoonLake Immunotherapeutics (MLTX).

Company-level read

Ticker impact

$MLTXNeutralMedium confidence
Context

SEC Form 4 shows CFO Matthias Bodenstedt sold 17,876 MLTX shares for ~$351.6K under a pre-arranged 10b5-1 plan (6/17–6/18).

Expected impact

Low likelihood of a sustained price move solely from this disclosure.

Evidence & confidence

The filing is a Form 4 insider transaction with explicit 10b5-1 pre-arrangement, which typically reduces interpretive value versus discretionary selling.

Market effects

Sector

No sector read-through; this is company-specific insider transaction data.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Even with 10b5-1, repeated insider selling can coincide with internal caution; traders may still watch for follow-on disclosures or changes in insider activity.

Key entities

  • issuer
    MoonLake Immunotherapeutics

    Subject of the Form 4 insider sale by its CFO.

  • insider
    Bodenstedt Matthias

    CFO who sold 17,876 shares of MLTX under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MLTX insider trading history →

Related articles

SEP 8
$MUMed

Dow, S&P 500, Nasdaq Futures Slip As Trump Calls Iran’s Peace Proposal ‘Totally Unacceptable’ — MU, SNDK, MRAM, MLTX Stocks In Focus

U.S. stock futures fell Sunday night after President Trump rejected Iran's peace proposal, raising concerns about global energy supplies. Dow, S&P 500, and Nasdaq futures declined, while oil prices rose. Micron (MU) and Sandisk (SNDK) shares surged over 5% due to high demand for memory chips. Everspin (MRAM) and MoonLake (MLTX) also saw significant gains.

stocktwits.com2 min
SEP 5
$MLTXMedAI 8/10

MLTX Stock Moves Higher As Traders Position For Late-Stage Trial Catalysts

MoonLake Immunotherapeutics (MLTX) shares rose 2.5% as investors anticipate late-stage trial results for its lead drug, sonelokimab, focusing on hidradenitis suppurativa. Full 52-week data is expected in Q2, with FDA submission planned for September 2026. Analysts' average price target is $27.62, implying 46% upside. MLTX stock has gained 63% this year, with retail sentiment turning bullish.

stocktwits.com2 min
AUG 11
$MLTXMed

MoonLake’s nanobody boosts PsA indication hopes after Phase III success

MoonLake Immunotherapeutics said its Phase III IZAR-1 trial of sonelokimab in biologic-naive adults with active psoriatic arthritis met the primary endpoint at week 16. In the 60 mg arm, 42.1% achieved ACR50. Secondary results included ACR20 66.5%, MDA 41.2%, PASI90 61%. Patients will be followed 52 weeks, with durability data expected in H1 2027. MoonLake is also running IZAR-2 versus AbbVie’s Skyrizi.

yahoo.com6 min
AUG 10
$MLTXMedAI 8/10

MoonLake's Sonelokimab Meets All Endpoints In Phase 3 PsA Trial

MoonLake Immunotherapeutics (MLTX) reported topline Phase 3 IZAR-1 results for Sonelokimab in biologic-naive adults with active psoriatic arthritis. The trial met the Week 16 primary endpoint, with 42.1% on 60 mg achieving ACR50. Secondary results included 66.5% ACR20, 41.2% MDA, and 61% PASI90. Safety showed no new signals. Full readout is expected in H1 2026.

rttnews.com3 min
AUG 10
$MLTXMedAI 8/10

Why is MoonLake Immunotherapeutics stock plunging today?

MoonLake Immunotherapeutics (MLTX) shares fell 21.7% pre-open to $14.30 after Phase 3 IZAR-1 topline results for sonelokimab in biologic-naive psoriatic arthritis met the primary endpoint. The company reported 42.1% ACR50 at Week 16, plus 66.5% ACR20 and 61% PASI90. Investors reacted negatively due to a BLA submission for hidradenitis suppurativa and future commercialization, with no current revenue and recent dilutive equity raises.

investing.com4 min
AUG 10
$MLTXMedAI 8/10

MoonLake reports positive Phase 3 PsA data and $537 million cash

MoonLake Immunotherapeutics (MLTX) reported positive topline Week 16 Phase 3 IZAR-1 results for sonelokimab 60 mg in biologic-naive adults with psoriatic arthritis, saying all clinical endpoints were met. It reported 42.1% ACR50 at Week 16 and Q2 2026 net loss of $61.8M, ending with $537.0M cash. R&D was $50.2M. It expects cash runway to mid-2028.

quiverquant.com4 min